Premium
P4‐220: Efficacy of high‐dose, extended‐release memantine (28 mg, once daily): Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease
Author(s) -
Graham Stephen,
Hendrix Suzanne,
Miller Michael,
Pejovic Vojislav,
Tocco Michael
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.2245
Subject(s) - memantine , placebo , post hoc analysis , medicine , percentile , randomized controlled trial , disease , dementia , pathology , statistics , alternative medicine , mathematics
MEMANTINE (28 MG, ONCE DAILY): POST HOC RESPONDER ANALYSIS FROM A RANDOMIZED TRIAL IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE Stephen Graham, Suzanne Hendrix, Michael Miller, Vojislav Pejovic, Michael Tocco, Forest Reseach Institute, Jersey City, New Jersey, United States; 2 Pentara Corporation, Salt Lake City, Utah, United States; 3 Prescott Medical Communications Group, Chicago, Illinois, United States; 4 Forest Research Institute, Jersey City, New Jersey, United States.